Navigation Links
Verenium To Present At Upcoming Conferences
Date:8/29/2012

SAN DIEGO, Aug. 29, 2012 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that members of its management team will be presenting at four upcoming conferences.

  • James Levine, President and Chief Executive Officer, will present at the 2012 Modern Energy Forum in Denver, Colorado on Wednesday, September 5, 2012. The presentation is scheduled to begin at 4:20 p.m. MT at the Ritz-Carlton, Denver and will not be webcast.
  • Mr. Levine will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 10, 2012.  The presentation is expected to begin at 11:15 a.m. ET and will take place at the Waldorf Astoria Hotel in New York City.
  • Mr. Levine will present at the MDB Capital Group's 3rd Annual Bright Lights Conference on Tuesday, September 11, 2012.  The presentation is expected to begin at 10:15 a.m. ET and will take place at the New York Palace Hotel in New York City.
  • Jeff Black, Senior Vice President and Chief Financial Officer, will present at the Wedbush Securities Clean Technology and Industrial Growth Management Access Conference in San Francisco, California on Wednesday, September 12, 2012.  The presentation is expected to begin at 3:05 p.m. PT and will take place at the Westin San Francisco, Market Street.

The live webcast of these presentations may be accessed by visiting the "Investors" section of Verenium's website at www.verenium.com. A webcast replay will be available approximately one hour after the live webcast end and will be accessible for 30 days following these conferences. 

About Verenium
Verenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes. Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets. Read more at www.verenium.com.

Forward-Looking Statements
Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty. These include, but are not limited to, statements related to Verenium's technology, products and product candidates and product pipeline, lines of business, operations (including Verenium's ability to successfully negotiate and enter into future collaborations and partnerships), capabilities, commercialization activities, customer adoption rates, industry conditions, future financial performance, and near-term and longer-term growth and prospects.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, risks associated with Verenium's strategic focus, technologies, products and product candidates and product pipeline (including Verenium's ability to identify, develop and commercialize new products and product candidates, either independently or with collaborators or partners, and market demand for those products and product candidates), dependence on patents and proprietary rights,  protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements,  its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies, the timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture or partnership agreements and licenses on a timely basis or at all, and risks and other uncertainties more fully described in Verenium's filings with the Securities and Exchange Commission, including, but not limited to, Verenium's annual report on Form 10-K for the year ended December 31, 2011 and any updates contained in its subsequently filed quarterly reports on Form 10-Q . These forward-looking statements speak only as of the date hereof, and Verenium expressly disclaims any intent or obligation to update these forward-looking statements.

Contacts:

Sarah Carmody

Manager, Corporate Communications
858-431-8581

sarah.carmody@verenium.com



'/>"/>
SOURCE Verenium Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Verenium To Present At The Jefferies 2012 Global Industrial And Aerospace & Defense Conference
2. Verenium To Present At The Deutsche Bank 2012 Clean Tech, Utilities & Power Conference
3. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
4. BioDelivery Sciences to Present at the Stifel Nicolaus 2012 Healthcare Conference
5. OncoSec to Present at the Rodman & Renshaw 2012 Annual Global Investment Conference
6. PAREXEL International to Present at Robert Baird Healthcare Conference
7. Vermillion to Present at the 2012 Gateway Conference on September 6
8. CVS Caremark To Present At Goldman Sachs 2012 Global Retailing Conference
9. Cynosure Announces Upcoming Conference Presentations
10. ADVENTRX Pharmaceuticals To Present At The Rodman & Renshaw Annual Global Investment Conference On September 10
11. Watson to Present at the Morgan Stanley 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016   Pulmatrix, Inc ., (NASDAQ: ... drugs, announced today that it was added to the ... its comprehensive set of U.S. and global equity indexes ... important milestone for Pulmatrix," said Chief Executive Officer ... our progress in developing drugs for crucial unmet medical ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: ... 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) assay ... sepsis or septic shock. With this clearance, Roche is ... a fully integrated solution for sepsis risk assessment and ... with bacterial infection and PCT levels in blood can ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief ... a minimum wage raise to $12 an hour by 2020 and then adjusting it yearly ... lost value of the minimum wage, assure the wage floor does not erode again, and ...
(Date:6/24/2016)... Georgia (PRWEB) , ... June 24, 2016 , ... ... awards today at the Clinical Decision Making in Emergency Medicine conference in Ponte ... have authored journal articles published in Emergency Medicine Practice and Pediatric ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Investment Group (TGIG), has initiated cultivation and processing operations at its production facility, ... Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of proactive ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone Partners ... extensive sequencing and genomics experience, as Vice President of North American Capital Sales at ... responsible for leading the sales team in the commercialization of the HTG EdgeSeq system ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... human induced pluripotent stem (iPS) cells and other difficult to transfect cells, announces ... Medium. The PluriQ™ G9™ Gene Editing System is a complete system ...
Breaking Medicine News(10 mins):